• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Onconova Therapeutic (NQ: ONTX )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, Apr 2, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Onconova Therapeutic

    < Previous 1 2 3 4 5 6 Next >
    Traws Pharma Announces New Employee Inducement Grants
    From Onconova Therapeutics, Inc.
    Via GlobeNewswire
    Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
    From Onconova Therapeutics, Inc.
    Via GlobeNewswire
    Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
    Translational science to characterize pathways impacted by rigosertib may help to guide future clinical studies and combination treatment regimen for difficult-to-treat cancers 
    From Onconova Therapeutics, Inc.
    Via GlobeNewswire
    Onconova Therapeutics's Earnings: A Preview
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
    Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion. 
    Via Benzinga
    Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
    From Onconova Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the... 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
    Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dipped 37.1% to $0.1599 in pre-market trading. Here are some... 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    It's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning! 
    Via InvestorPlace
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
    From Onconova Therapeutics, Inc.
    Via GlobeNewswire
    Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
    From Onconova Therapeutics, Inc.
    Via GlobeNewswire
    Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
    From Onconova Therapeutics, Inc.
    Via GlobeNewswire
    Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
    Company to host conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2023 
    From Onconova Therapeutics, Inc.
    Via GlobeNewswire
    Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
    From Onconova Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Onconova Expands Leadership Team with Two Key Appointments
    From Onconova Therapeutics, Inc.
    Via GlobeNewswire
    Promising Preclinical Narazaciclib Data Presented at MCL Meeting
    From Onconova Therapeutics, Inc.
    Via GlobeNewswire
    Encouraging Rigosertib Data Presented at EADV as Late Breaker
    Reporting responses in patients with RDEB-associated SCC, a devastating disease with a significant unmet need 
    From Onconova Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
    From Onconova Therapeutics, Inc.
    Via GlobeNewswire
    Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
    From Onconova Therapeutics, Inc.
    Via GlobeNewswire
    Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results
    From Onconova Therapeutics, Inc.
    Via GlobeNewswire
    Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023
    Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 10, 2023 
    From Onconova Therapeutics, Inc.
    Via GlobeNewswire
    Earnings Scheduled For August 10, 2023
    Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
    Via Benzinga
    Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma
    Narazaciclib demonstrated significant synergistic anti-cancer activity in multiple in vivo models of mantle cell lymphoma (MCL) when combined with ibrutinib, the current standard-of-care 
    From Onconova Therapeutics, Inc.
    Via GlobeNewswire
    Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting
    Trial in Progress poster detailed design of Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa 
    From Onconova Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.